Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors.

Authors

Lawson Eng

Lawson Eng

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

Lawson Eng , Katrina Hueniken , M. Catherine Brown , Andrew Hope , Meredith Elana Giuliani , Peter Selby , Kelvin K. Chan , Nicole Mittmann , Wei Xu , David Paul Goldstein , Geoffrey Liu , John R. de Almeida

Organizations

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada, Centre for Addiction and Mental Health, Toronto, ON, Canada, Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, Toronto, ON, Canada, HOPE Research Centre, Sunnybrook Hospital, Toronto, ON, Canada, Department of Otolaryngology-Head & Neck Surgery/Surgical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada

Research Funding

Other

Background: Health behavior changes including tobacco cessation and increasing physical activity (PA) are important aspects of cancer survivorship. Understanding how these behaviours impact on HU and financial toxicity will help when evaluating survivorship programs. We evaluated the impact of tobacco cessation and PA on HU, function and financial toxicity among HNC patients (pts). Methods: HNC pts from Princess Margaret Cancer Centre completed questionnaires at baseline (diagnosis) and 12 months between 2014-2018 evaluating tobacco use, PA with the Godin questionnaire, cancer related monthly out of pocket costs (OOPC), HU using HU Index Mark 3, function using Lawton Brody Scale (LBS) and lost annual income. Multivariable linear regression analyses evaluated the impact of health behaviour change on OOPC, HU, LBS and lost income. Results: Among 296 pts, mean age 61, 76% male; 29% smoked at diagnosis, 60% quit 1 year after; 26% met PA guidelines at diagnosis, 52% continued to meet guidelines at 1 year. 19% of those not meeting PA guidelines at diagnosis, met them at 1 year. Among all, mean HU [SEM] was 0.84 [0.01] (baseline), 0.80 [0.01] (12 months); mean monthly OOPC [SEM] were $171 [27] (12 months); mean annual lost individual income was $25897 [2945]. Among smokers at diagnosis, those continuing to smoke at 1 year lost a mean of $21272 (95% CI [$2783-39761] P= 0.03) more in individual annual income compared to pts who quit, adjusted for baseline income and education. Current smokers who quit smoking at 1 year had an adjusted mean increase in HU of 0.15 ([0.00-0.30] P= 0.05) greater than pts continuing to smoke. Pts who continued meeting PA guidelines at 1 year had an adjusted mean increase in HU scores of 0.11 ([0.02-0.20], P= 0.02) compared to those reducing PA levels after diagnosis. Changes in PA and tobacco were not associated with change in function or OOPC; improving to meet PA guidelines after diagnosis was not associated with HU or lost income (P> 0.05). Conclusions: Quitting smoking and maintaining PA levels after diagnosis were associated with improvements in HU scores; quitting smoking reduced lost income. Cancer survivors should be made aware of the potential economic impact of behaviour change.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Health Promotion/Behaviors

Citation

J Clin Oncol 37, 2019 (suppl; abstr 11561)

DOI

10.1200/JCO.2019.37.15_suppl.11561

Abstract #

11561

Poster Bd #

253

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Quality Care Symposium

The role of primary care in opioid prescribing for head and neck cancer (HNC) survivors.

First Author: Talya Salz

Abstract

2024 ASCO Annual Meeting

Timeframe for lymphedema therapy for head and neck cancer survivors.

First Author: Cristina Kline-Quiroz

Abstract

2024 ASCO Quality Care Symposium

Opioid tapering and discontinuation for head and neck cancer (HNC) survivors.

First Author: Talya Salz

First Author: Celeste K Nsubayi